How does bimatoprost compare to minoxidil for hair regrowth?

In the 1960s, the pharmaceutical company Upjohn was developing a treatment for resistant hypertension. That's how oral minoxidil was born, marketed in 1979 as Loniten, a potent vasodilator. Many patients began experiencing body and scalp hair growth — an unexpected side effect that quickly turned into an opportunity. In 1988, the U.S. Food and Drug Administration (FDA) approved a 2% topical version for male androgenetic alopecia, and in 1991, its use was extended to women. What began as a cardiovascular treatment became, after a series of discoveries and regulatory shifts, one of the most widely used hair loss treatments. Bimatoprost, on the other hand, originated in 2001 as a prostaglandin analog developed to treat glaucoma by lowering intraocular pressure. A few years later, patients reported a visible increase in eyelash growth. That observation led to its FDA approval in 2008 for cosmetic use to lengthen and thicken eyelashes.

A Different Path to the Scalp: Two Drugs, Two Very Different Journeys

Although both are now used on the scalp, their paths could not be more different. Minoxidil emerged from an antihypertensive setting and gained global approval after extensive studies. Bimatoprost came from ophthalmology, with a less direct trajectory and, on the scalp, only experimental use. Minoxidil, in its 5% topical version, is described in review articles as shortening the resting (telogen) phase and prolonging the follicle's growth phase (anagen), which increases hair density and thickness; it is a potassium-channel opener and vasodilator, and reviewers note its full mechanism in hair is still not settled. Bimatoprost, in contrast, is an analog of prostamide F2α and is also reported to stimulate the anagen phase, but it has no approved indication for scalp application.

What Science Says: Comparing the Two in Clinical Studies

A small randomized study published in the Indian Journal of Public Health Research & Development in 2018 compared topical 0.03% bimatoprost and 5% minoxidil in 16 men with androgenetic alopecia over 12 weeks — two groups of eight. Researchers measured terminal hair count and hair shaft diameter at baseline and during follow-up.

Both treatments were reported to increase terminal hair diameter and count over the 12 weeks, and the authors reported no significant side effects. The sample size (eight participants per group) and the short duration mean the study cannot support any long-term conclusion, and it has not been replicated at scale.

A larger randomized controlled trial by Zaky and colleagues (2023, Archives of Dermatological Research) compared minoxidil 2% gel with bimatoprost 0.01% and 0.03% gels for eyebrow hypotrichosis in 60 adults, 20 per group. All three groups improved significantly on the Global Eyebrow Assessment (GEBA) scale, and the differences between groups were not statistically significant (P = 0.091, 0.102 and 0.663). The authors concluded that bimatoprost was as effective as minoxidil for eyebrows, but a trial of 20 people per arm that fails to find a difference cannot show that two treatments are equally effective. The study looked at eyebrows, not the scalp, and ran short — both are important limits on what it can tell you about pattern hair loss.

Minoxidil has been supported by dozens of trials since the 1980s. These studies typically involved hundreds of participants, with follow-up of up to 48 weeks, and used standardized hair counts, photographic assessments, and dermatological grading.

That body of research led to FDA approval in 1988 and established minoxidil as a first-line treatment for androgenetic alopecia. Research into bimatoprost's effects on the scalp, by contrast, is thin: the published scalp studies are small, much of the published work looks at eyebrows or alopecia areata rather than the pattern baldness minoxidil is approved for, and the larger sponsor trials exist only as registry results. The largest direct comparison is Allergan's registered phase 2 trial NCT01325337, in 307 men with androgenetic alopecia. At 6 months, minoxidil 5% added about 22 hairs in the target area, against 6 to 13 for three bimatoprost formulations and 4 for vehicle. The trial was never published in a journal. The scalp studies also lack long-term follow-up and large-scale evaluation, which is why reviewers describe their findings as preliminary rather than conclusive.

Minoxidil remains the most extensively studied and widely used topical hair loss treatment worldwide.

It requires ongoing use: if it is discontinued, the reported benefits usually fade within a few months. Documented side effects include scalp irritation, changes in hair texture, and unwanted facial hair growth in some users. Bimatoprost has a documented effect on eyelash and eyebrow growth. On the scalp, though, it remains experimental. The evidence there is preliminary, with no large-scale or long-duration published studies supporting its use in pattern hair loss. It is not approved by the FDA or any other major regulatory body for that indication.

So, Which One Is Better for Hair Regrowth?

On the available evidence and regulatory approvals, minoxidil is the better-supported option for scalp hair regrowth. Though it was originally developed for hypertension, it went through large-scale testing that led to approval and decades of use in hair loss. Bimatoprost, originally an eye drop for glaucoma, has published evidence for stimulating growth at the eyelashes and eyebrows. Laboratory and mouse research suggests it acts on scalp follicles, but in the one large registered head-to-head trial it produced smaller gains than minoxidil 5%, and it is not on equal footing with minoxidil in evidence or approval.

User Experiences: Bimatoprost vs Minoxidil for Hair Regrowth

The Tressless community has been actively discussing bimatoprost, a prostaglandin analog originally used to treat glaucoma and promote eyelash growth, in comparison with minoxidil, a long-standing and widely used topical treatment for androgenetic alopecia. Across multiple user posts, bimatoprost comes up as an intriguing alternative or adjunct to minoxidil, especially among those experimenting with less common stacks or frustrated by the limits of traditional treatments.

In one discussion, a user described a combined formula of minoxidil and bimatoprost (0.3 mg/mL, which is the 0.03% ophthalmic strength) applied once daily. They pointed to research they read as suggesting bimatoprost could outperform minoxidil on hair density; no published head-to-head scalp trial supports that. Another user named a commercial serum that a dermatologist had suggested; its ingredients and claims have not been independently verified. In that user's account the dermatologist had advised against finasteride in their particular case — a decision made for one person, not a general rule.

In a broader thread titled "Minoxidil Alternative?" users discussed bimatoprost and related drugs like latanoprost, noting that these compounds work through a different mechanism than minoxidil or finasteride and might help convert vellus hairs to terminal hairs, particularly at the hairline. Concerns were raised about high cost and the lack of long-term efficacy data. One user reported home-made bimatoprost 1% and 3% solutions and claimed better regrowth than minoxidil 5%. Some community members do compound their own solutions at these strengths; that is 33 to 100 times the approved 0.03% concentration, it is unregulated, it has never been tested on the scalp in a published trial, and the known effects of bimatoprost — skin and iris pigmentation changes, loss of fat around the eye socket, eye irritation — are listed on the Latisse label at the 0.03% strength. No study has measured how often they occur at 1–3% on the scalp, and higher strengths should not be assumed to be safer. The label says the iris darkening is likely to be permanent. Another thread summarized user skepticism about and interest in prostaglandin analogs, with bimatoprost described as possibly most useful for specific areas such as the hairline, where users find minoxidil less helpful. The prevailing view in those threads is that it does not replace a DHT blocker and may work best as part of a combination.

The community has also discussed a company planning a topical combining minoxidil, finasteride, and bimatoprost, which points to a broader trend toward single-formulation stacks. No such combination has been approved by a regulator, and combining prescription drugs topically is a decision for a prescriber.

Bimatoprost is a prescription medicine and its use on the scalp is off-label. Talk to a doctor or pharmacist before starting, stopping or combining bimatoprost or minoxidil, particularly if you have an eye condition or already use other hair-loss treatments.

References

Zaky, M. S., Hashem, O. A., Mahfouz, S. M., & Elsaie, M. L. (2023). Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial. Archives of Dermatological Research, 315(9), 2635–2641. PMID: 37517060. https://pmc.ncbi.nlm.nih.gov/articles/PMC10514173/

Tabri, F., Anwar, A. I., Adriani, A., & Aryaningrum, D. (2018). The effectiveness of 0.03% bimatoprost solution vs minoxidil 5% in androgenic alopecia. Indian Journal of Public Health Research & Development, 9(12), 1444–1448. https://doi.org/10.5958/0976-5506.2018.02056.9

ClinicalTrials.gov. Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia. NCT01325337 (results posted). https://clinicaltrials.gov/study/NCT01325337

U.S. National Library of Medicine, DailyMed. LATISSE (bimatoprost ophthalmic solution) 0.03%, prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34f83d9d-2c64-463e-8a90-9a460fedfead

Zeppieri, M., Gagliano, C., Spadea, L., Salati, C., Chukwuyem, E. C., et al. (2024). From Eye Care to Hair Growth: Bimatoprost. Pharmaceuticals, 17(5), 561. https://doi.org/10.3390/ph17050561

Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy, 13, 2777–2786. PMID: 31496654. https://pmc.ncbi.nlm.nih.gov/articles/PMC6691938/